InProTher is developing first-in-class immunotherapies against cancer and has pre-clinical proof of concept for broad and curative cancer therapy.
Treated animals eliminate their tumors and become resistant to challenge from administered cancer cells.
A combination with immune checkpoint inhibitors makes the effect complete in animal models. InProTher's research is based upon research by Associate Professor Peter Johannes Holst and colleagues and international collaborators.
Location: Denmark
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | SeedFolio | seedfolio.... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 24.05.2023 | InProTher Raises EUR6M in Seed Financing | InProTher, a Copenhagen, Denmark-based early-stage biotechnology company developing effective immuno... | finsmes.co... |
| 04.02.2020 | SIRION Biotech Licenses Adenovirus Technology to Danish Star... | Five years of collaborative discovery work comes to fruition MUNICH & COPENHAGEN, Denmark–(BUSI... | venturebea... |
| - | InProTher | “InProTher – InProTher treats cancer by target tumor virus within the human genome.” | fastfounde... |